Treatments for benign prostatic hyperplasia
US11974979B2 · kind B2 · utility
0Cited by
27References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 22, 2022 |
| Grant date | May 7, 2024 |
| Priority date | — |
| Expiry date | Apr 22, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2300/416
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.